Biogen (BIIB) PT Raised to $300 at Wedbush, After FDA Approves Aduhelm (Aducanumab)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $250.67 +0.67%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $240.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Biogen (BIIB) PT Raised to $278 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
